The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Among three MAPK families, paroxetine was found to be able to decrease the phosphorylation of
ERK. It was reported that paroxetine attenuates the symptoms of collage induced arthritis
rats due to its inhibitory effect on T cell activation and infiltration to synovial tissue
via suppression of ERK pathway. This study aimed to evaluate the therapeutic efficacy of
paroxetine in rheumatoid arthritis. Paroxetine prevents the joint inflammation which is at
the very early stage. paroxetine could inhibit GRK2 with selectivity over other GRKs.
Medications developed for maintaining the immunologic equilibrium. such as GRK2 inhibitors,
will be the novel trends in RA treatment that could avoid the adverse side effects that are
common with current treatment options.